June 9, 2020 / 11:54 AM / a month ago

BRIEF-Evox Announces A Multi-Target RNAI & Antisense Research Collaboration And License Agreement With Lilly

June 9 (Reuters) - Evox Therapeutics:

* EVOX THERAPEUTICS - ANNOUNCES A MULTI-TARGET RNAI & ANTISENSE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH LILLY

* EVOX THERAPEUTICS - UNDER TERMS, EVOX TO GET $20 MILLION CASH UP-FRONT PAYMENT, RESEARCH FUNDING OVER 3 YRS

* EVOX THERAPEUTICS - TO GET $10 MILLION INVESTMENT FROM LILLY IN EXCHANGE FOR A CONVERTIBLE BOND FROM CO

* EVOX THERAPEUTICS - TO BE ELIGIBLE FOR POTENTIAL PRE-CLINICAL, CLINICAL DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES OF UP TO ABOUT $1.2 BILLION

* EVOX THERAPEUTICS - TO BE ELIGIBLE FOR TIERED ROYALTIES UP TO LOW DOUBLE DIGITS ON NET SALES OF PRODUCTS ARISING FROM COLLABORATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below